These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 34374173)

  • 1. Alemtuzumab in multiple sclerosis: A retrospective analysis of occult hemorrhagic magnetic resonance imaging lesions and risk factors.
    Bachmann H; Cambron M; Casselman JW; Van Driessche V; Van Haute E; Van Hijfte L; Kelderman T; Hemelsoet D; Laureys G
    Eur J Neurol; 2021 Dec; 28(12):4209-4213. PubMed ID: 34374173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A real-life study of alemtuzumab in persons with multiple sclerosis: Kuwait's experience.
    Alroughani R; AlMojel M; Al-Hashel J; Ahmed SF
    Mult Scler Relat Disord; 2023 Jun; 74():104712. PubMed ID: 37054581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute infusion effects in relapsing multiple sclerosis patients receiving alemtuzumab under a modified prophylaxis regimen.
    Leckey R; Borsellino L; Rawlings AM; Ashkenas J; Suri A
    Mult Scler Relat Disord; 2022 Oct; 66():104030. PubMed ID: 35870368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alemtuzumab for relapsing multiple sclerosis in clinical practice: A four-year retrospective one-center study.
    Rodríguez de Castro B; Pampín Sánchez R; Tembrás Martinez S; Ayastuy Ruiz A; Martínez-Múgica Barbosa C
    Int J Risk Saf Med; 2020; 31(4):259-265. PubMed ID: 32145001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).
    Vukusic S; Brassat D; de Seze J; Izquierdo G; Lysandropoulos A; Moll W; Vanopdenbosch L; Arque MJ; Kertous M; Rufi P; Oreja-Guevara C
    Mult Scler Relat Disord; 2019 Apr; 29():7-14. PubMed ID: 30654246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracerebral haemorrhage during alemtuzumab administration.
    Azevedo CJ; Kutz C; Dix A; Boster A; Sanossian N; Kaplan J
    Lancet Neurol; 2019 Apr; 18(4):329-331. PubMed ID: 30777657
    [No Abstract]   [Full Text] [Related]  

  • 7. Induction of disease remission with one cycle of alemtuzumab in relapsing-remitting MS.
    Kocsik AS; Klein DE; Liedke M; Kaunzner UW; Nealon NM; Gauthier SA; Vartanian T; Perumal JS
    J Neurol; 2018 May; 265(5):1226-1229. PubMed ID: 29666985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of alemtuzumab in the treatment of active relapsing-remitting multiple sclerosis: a multicenter, observational study.
    Brecl Jakob G; Barun B; Gomezelj S; Gabelić T; Šega Jazbec S; Adamec I; Horvat Ledinek A; Rot U; Krbot Skorić M; Habek M
    Neurol Sci; 2021 Nov; 42(11):4591-4597. PubMed ID: 33660157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of alemtuzumab treatment in a real-world cohort of patients with multiple sclerosis.
    Zmira O; Halpern AI; Abraham L; Achiron A
    Acta Neurol Belg; 2021 Dec; 121(6):1513-1518. PubMed ID: 32447722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of alemtuzumab and natalizumab in the treatment of different stages of multiple sclerosis patients.
    Wang L; Qi CH; Zhong R; Yuan C; Zhong QY
    Medicine (Baltimore); 2018 Feb; 97(8):e9908. PubMed ID: 29465579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alemtuzumab-induced autoimmune thyroid events in patients with relapsing-remitting multiple sclerosis: A real-life and monocentric experience at a tertiary-level centre.
    Manso J; Zhu YH; Margoni M; Rinaldi F; Censi S; Carducci S; Cosma C; Plebani M; Gallo P; Mian C
    Clin Endocrinol (Oxf); 2022 Sep; 97(3):331-338. PubMed ID: 34724236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Assessment of the efficacy and safety of alemtuzumab in patients with highly active relapsing-remitting multiple sclerosis in Russian population].
    Sivertseva SA; Prilenskaya AM; Popova EV; Turova EL; Volkova LI; Smagina IV; Elchaninova EY; Afanas'eva AI; Goncharova ZA; Markova EA; Yarosh NM; Bakhtiiarova KZ; Sherman MA; Boyko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(9):76-82. PubMed ID: 37796071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.
    ; Coles AJ; Compston DA; Selmaj KW; Lake SL; Moran S; Margolin DH; Norris K; Tandon PK
    N Engl J Med; 2008 Oct; 359(17):1786-801. PubMed ID: 18946064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alemtuzumab for the treatment of multiple sclerosis.
    Evan JR; Bozkurt SB; Thomas NC; Bagnato F
    Expert Opin Biol Ther; 2018 Mar; 18(3):323-334. PubMed ID: 29309202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic erythematous lupus after treatment of multiple sclerosis with alemtuzumab.
    Adamec I; Mayer M; Ćorić M; Ruška B; Habek M
    Mult Scler Relat Disord; 2020 Nov; 46():102589. PubMed ID: 33296985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study.
    Frau J; Saccà F; Signori A; Baroncini D; Fenu G; Annovazzi P; Capobianco M; Signoriello E; Laroni A; La Gioia S; Sartori A; Maniscalco GT; Bonavita S; Clerico M; Russo CV; Gallo A; Lapucci C; Carotenuto A; Sormani MP; Cocco E;
    J Neurol; 2019 Oct; 266(10):2440-2446. PubMed ID: 31209573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early neutropenia with thrombocytopenia following alemtuzumab treatment for multiple sclerosis: case report and review of literature.
    Maniscalco GT; Cerillo I; Servillo G; Napolitano M; Guarcello G; Abate V; Improta G; Florio C
    Clin Neurol Neurosurg; 2018 Dec; 175():134-136. PubMed ID: 30419425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alemtuzumab induced hemodynamic change in relapsing multiple sclerosis occurs independent of corticosteroid premedication - a retrospective multicentre study.
    Di Pauli F; Riedl K; Hegen H; Auer M; Berek K; Krajnc N; Leutmezer F; Zinganell A; Berger T; Deisenhammer F; Bsteh G
    Mult Scler Relat Disord; 2022 Jul; 63():103810. PubMed ID: 35477127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis.
    Brown JW; Coles AJ
    Drug Des Devel Ther; 2013; 7():131-8. PubMed ID: 23494602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Autoimmune Thyroid Disease in Multiple Sclerosis Patients Post-Alemtuzumab Improves Treatment Response.
    Sovetkina A; Nadir R; Scalfari A; Tona F; Murphy K; Rigoni E; Dorsey R; Malik O; Nandoskar A; Singh-Curry V; Nicholas R; Martin N
    J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32667988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.